Compare different lead molecules showing functional activity using a single PBMC donor for the study.
Compare lead candidates to current standard of care therapies and determine which molecule / dosage provides minimal toxicity by using pre-characterized PBMC donors.
Test the optimal dosages against the diversity of the population by using multiple PBMC donors in the study.
In vivo CRS assays can help reduce risks and speed up the process of delivering effective therapies to patients. By using these assays, drug developers not only can evaluate the risk-benefit ratio of preclinical candidates but also identify the most promising lead compounds early in the development pipeline, so they can allocate resources more effectively and advance to clinical stages more quickly and confidently.
Not what you're looking for?
Visit our Resource Hub
